181 related articles for article (PubMed ID: 9789565)
1. The mechanism of ATP-dependent multidrug transport by P-glycoprotein.
Shapiro AB; Ling V
Acta Physiol Scand Suppl; 1998 Aug; 643():227-34. PubMed ID: 9789565
[TBL] [Abstract][Full Text] [Related]
2. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities.
Shapiro AB; Ling V
Eur J Biochem; 1997 Nov; 250(1):130-7. PubMed ID: 9432000
[TBL] [Abstract][Full Text] [Related]
3. Transport of LDS-751 from the cytoplasmic leaflet of the plasma membrane by the rhodamine-123-selective site of P-glycoprotein.
Shapiro AB; Ling V
Eur J Biochem; 1998 May; 254(1):181-8. PubMed ID: 9652412
[TBL] [Abstract][Full Text] [Related]
4. Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-MDR1 cell monolayers.
Tang F; Ouyang H; Yang JZ; Borchardt RT
J Pharm Sci; 2004 May; 93(5):1185-94. PubMed ID: 15067695
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site.
Shapiro AB; Fox K; Lam P; Ling V
Eur J Biochem; 1999 Feb; 259(3):841-50. PubMed ID: 10092872
[TBL] [Abstract][Full Text] [Related]
6. Lipid bilayer properties control membrane partitioning, binding, and transport of p-glycoprotein substrates.
Clay AT; Sharom FJ
Biochemistry; 2013 Jan; 52(2):343-54. PubMed ID: 23268645
[TBL] [Abstract][Full Text] [Related]
7. Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein.
Shapiro AB; Ling V
Eur J Biochem; 1998 May; 254(1):189-93. PubMed ID: 9652413
[TBL] [Abstract][Full Text] [Related]
8. Drug transport by reconstituted P-glycoprotein in proteoliposomes. Effect of substrates and modulators, and dependence on bilayer phase state.
Lu P; Liu R; Sharom FJ
Eur J Biochem; 2001 Mar; 268(6):1687-97. PubMed ID: 11248688
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer.
Shapiro AB; Corder AB; Ling V
Eur J Biochem; 1997 Nov; 250(1):115-21. PubMed ID: 9431998
[TBL] [Abstract][Full Text] [Related]
10. Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site.
Lugo MR; Sharom FJ
Biochemistry; 2005 Jan; 44(2):643-55. PubMed ID: 15641790
[TBL] [Abstract][Full Text] [Related]
11. Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein.
Shapiro AB; Ling V
Eur J Biochem; 1997 Nov; 250(1):122-9. PubMed ID: 9431999
[TBL] [Abstract][Full Text] [Related]
12. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein (ABCB1) interacts directly with lipid-based anti-cancer drugs and platelet-activating factors.
Eckford PD; Sharom FJ
Biochem Cell Biol; 2006 Dec; 84(6):1022-33. PubMed ID: 17215888
[TBL] [Abstract][Full Text] [Related]
14. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.
Wang E; Casciano CN; Clement RP; Johnson WW
Cancer Res; 2001 Oct; 61(20):7525-9. PubMed ID: 11606389
[TBL] [Abstract][Full Text] [Related]
15. Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein.
Maki N; Moitra K; Silver C; Ghosh P; Chattopadhyay A; Dey S
Biochemistry; 2006 Feb; 45(8):2739-51. PubMed ID: 16489767
[TBL] [Abstract][Full Text] [Related]
16. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state.
Ramachandra M; Ambudkar SV; Chen D; Hrycyna CA; Dey S; Gottesman MM; Pastan I
Biochemistry; 1998 Apr; 37(14):5010-9. PubMed ID: 9538020
[TBL] [Abstract][Full Text] [Related]
17. Transition state P-glycoprotein binds drugs and modulators with unchanged affinity, suggesting a concerted transport mechanism.
Qu Q; Chu JW; Sharom FJ
Biochemistry; 2003 Feb; 42(5):1345-53. PubMed ID: 12564938
[TBL] [Abstract][Full Text] [Related]
18. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.
Lee JS; Paull K; Alvarez M; Hose C; Monks A; Grever M; Fojo AT; Bates SE
Mol Pharmacol; 1994 Oct; 46(4):627-38. PubMed ID: 7969041
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells.
Chen Y; Pant AC; Simon SM
Cancer Res; 2001 Nov; 61(21):7763-9. PubMed ID: 11691790
[TBL] [Abstract][Full Text] [Related]
20. Microplate screening of the differential effects of test agents on Hoechst 33342, rhodamine 123, and rhodamine 6G accumulation in breast cancer cells that overexpress P-glycoprotein.
Sarver JG; Klis WA; Byers JP; Erhardt PW
J Biomol Screen; 2002 Feb; 7(1):29-34. PubMed ID: 11897053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
